Valneva SE (VALN) News and press releases

HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $22 Price Target

30 May 23

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $22 price target.

HC Wainwright & Co. Maintains Buy on Valneva, Lowers Price Target to $22

5 May 23

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Edward White maintains Valneva (NASDAQ:VALN) with a Buy and lowers the price target from $25 to $22.

Why Synaptics Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

4 May 23

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares jumped 89.3% to $7.44.

12 Health Care Stocks Moving In Thursday's Intraday Session

4 May 23

Movers

Zillow, Shopify, Datadog And Other Big Stocks Moving Higher On Thursday

4 May 23

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

U.S. stocks traded lower, with the Dow Jones falling around 400 points on Thursday. Here are some big stocks recording gains in today’s session.

Earnings Scheduled For May 4, 2023

4 May 23

Earnings

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.

Valneva Q1 EPS $(0.28) Up From $(0.52) YoY, Sales $35.96M Up From $24.52M YoY

4 May 23

Earnings, News

Valneva (NASDAQ:VALN) reported quarterly losses of $(0.28) per share. This is a 46.15 percent increase over losses of $(0.52) per share from the same period last year. The company reported $35.96 million in sales this

Stocks That Hit 52-Week Lows On Wednesday

26 Apr 23

Options

On Wednesday, 345 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

24 Mar 23

Options

On Friday, 469 companies hit new 52-week lows.

Valneva Expects FY23 Sales Of €220M-€260M Down From €361.3 In 2022

23 Mar 23

Biotech, Earnings, News, Guidance, Health Care, General

Sales Guidance includes €130 million to €150 million of product sales, including marginal COVID-19 vaccine sales under an existing supply agreement with the Kingdom of Bahrain Between €90 million

Valneva FY EPS €(1.24) Down From €(0.75) YoY, Sales €361.30M Up From €348.10M YoY

23 Mar 23

Earnings, News

Valneva (NASDAQ:VALN) reported quarterly losses of €(1.24) per share. This is a 65.33 percent decrease over losses of €(0.75) per share from the same period last year. The company reported €361.30 million

Overview Of Value Stocks In The Healthcare Sector

13 Mar 23

News

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

31 May 23

Press Releases

Saint-Herblain (France), May 31, 2023 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will attend the Jefferies Healthcare Conference (June 7-9 in New York),

Valneva Announces the Availability of Documentation for its Shareholder Meeting

31 May 23

Press Releases

Saint-Herblain (France), May 31, 2023 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced the availability of documentation for its Combined General Meeting to be held on June 21, 2023 at

Valneva Files for Chikungunya Vaccine Authorization with Health Canada

30 May 23

Press Releases, General

Saint-Herblain (France), May 30, 2023 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announces the filing of a regulatory application with Health Canada for marketing approval of the Company's

Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates

4 May 23

Earnings, Press Releases

Product sales increased 98.6% to €32.1 million in the first quarter of 2023 compared to €16.2 million in the first quarter of 2022 Driven by IXIARO® and DUKORAL® sales both of which more than quadrupled

Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F

31 Mar 23

News, Press Releases

Saint-Herblain (France), March 31, 2023 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, announced today the filing, on March 30 2023, of its 2022 Universal Registration Document (URD) with the French

Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.

30 Mar 23

Press Releases

Saint Herblain (France), March 30, 2023 –Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, announced today it will present on its single-shot chikungunya vaccine candidate, VLA1553, and host a roundtable

Valneva Reports Full Year 2022 Results and Provides Corporate Updates

23 Mar 23

Earnings, Press Releases

Total revenues of €361.3 million in 2022 compared to €348.1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales and €29.6 million